InstalabLoading...
InstalabLoading...
If you have spent time outdoors in an area where ticks carry Lyme disease and you develop unexplained symptoms, one of the first questions is whether your body has begun fighting the infection. The Lyme IgM (immunoglobulin M) antibody test looks for the earliest wave of immune proteins your body produces after encountering Borrelia burgdorferi, the spiral-shaped bacterium transmitted by tick bites. A positive result can support a diagnosis of recent infection, but this test comes with an unusually high rate of misleading results that you need to understand before acting on any single reading.
Unlike most blood markers covered on this site, the Lyme IgM test is not a number you track for prevention or optimization. It is a diagnostic test designed to answer a specific yes-or-no question: has your immune system recently mounted a response to Borrelia? That question sounds simple, but the biology behind the answer is anything but.
Your immune system produces several classes of antibodies when it detects an invader. IgM (immunoglobulin M) is typically the first type to appear. In the context of Lyme disease, the test detects IgM antibodies targeted at specific proteins on the surface of Borrelia burgdorferi, including proteins called OspC, VlsE, and flagellin. These IgM antibodies are made by B cells, a type of white blood cell that lives in your lymph nodes and other immune tissues.
After IgM, your immune system usually switches to producing IgG (immunoglobulin G) antibodies, which are more precise and longer lasting. In theory, IgM should appear first and then fade as IgG takes over. In practice, however, Lyme IgM antibodies can persist for years after the infection has been treated and resolved. A large registry study of over 34,000 people in Sweden and Denmark found that IgM antibodies could remain detectable for a median of 2 to 7 years depending on the initial level, and a study of 79 patients found that 10 to 15% still had detectable IgM 10 to 20 years after their original Lyme infection.
The single most important thing to understand about this test is its high false positive rate. A false positive means the test says you have Lyme antibodies when you actually do not have and may never have had Lyme disease. This happens for several well-documented reasons.
First, the OspC protein that many IgM tests target contains a short sequence (called PKKP) that also appears in unrelated human, bacterial, and even plant proteins. Your immune system can produce antibodies against these look-alike sequences during completely unrelated illnesses or even in the absence of any illness at all. A study of 59 people with persistent IgM but no evidence of Lyme disease traced their false positives to this cross-reactivity.
Second, active infections with common viruses like Epstein-Barr virus (which causes mono), cytomegalovirus, and BK virus can trigger positive Lyme IgM results through a process called polyclonal B cell activation, where your immune system produces a flood of diverse antibodies that happen to react with Lyme test antigens. A study of 69 patients with active viral infections found frequent false positive Lyme IgM and IgG results, especially against the flagellin and OspC proteins.
Third, the numbers are stark. In one clinical evaluation, a common type of automated screening blood test (chemiluminescent assay) had an estimated false positive rate of about 80%. When IgM immunoblot (a more detailed confirmation test that separates out individual antibody targets) was used, the false positive rate was still about 25%. In a Swedish cohort, half of all diagnoses based on isolated IgM positivity were judged incorrect on careful clinical review. A study of patients referred to an infectious disease clinic found that 27.5% had false positive IgM immunoblots, and more than three-quarters of those patients received unnecessary antibiotics as a result.
The test's sensitivity, meaning its ability to detect true Lyme cases, is moderate at best and varies by disease stage. A European meta-analysis pooling data across multiple studies found that for the classic Lyme rash (erythema migrans), IgM sensitivity was only about 43%. For Lyme affecting the nervous system (neuroborreliosis), sensitivity improved to about 60%. For Lyme arthritis, IgM sensitivity dropped to roughly 39%, while IgG testing caught about 94% of cases at that stage.
| Disease Stage | IgM Sensitivity | IgG Sensitivity |
|---|---|---|
| Erythema migrans (skin rash) | About 43% | Lower in early stage |
| Neuroborreliosis (nervous system) | About 60% | Higher in later disease |
| Lyme arthritis (joints) | About 39% | About 94% |
Specificity, the ability to correctly identify people who do not have Lyme, runs around 95% for IgM. That sounds high, but in a population where Lyme is uncommon (which includes most of the United States outside the Northeast and upper Midwest), even 95% specificity means that a large share of positive results will be false positives. In low-prevalence populations, the chance that a positive IgM result actually reflects real Lyme disease (called positive predictive value) can fall below 4%.
Lyme IgM results are reported differently depending on the testing algorithm your lab uses, but they generally fall into one of two frameworks.
In the standard two-tier testing (STTT) approach, a screening test (usually an enzyme-based blood test called an enzyme immunoassay, or a chemiluminescent assay) is performed first. If that screening test is positive or borderline, a Western blot (immunoblot) is run as a confirmation step. The Western blot separates out individual proteins and checks which ones your antibodies react to. For IgM, a positive Western blot typically requires reactivity to at least 2 of 3 specific protein bands. For IgG, the criteria require 5 of 10 bands.
In the newer modified two-tier testing (MTTT) approach, two different enzyme-based blood tests are run in sequence, often focused on IgG targets like VlsE and C6 peptide. This approach has been shown to match or exceed the sensitivity of the standard method while maintaining high specificity, and it often eliminates the need for a separate IgM blot entirely. A study of nearly 1,500 samples found that using two sequential IgG-focused enzyme-based tests provided comparable sensitivity to C6 testing while preserving the specificity of standard two-tier testing.
Because there is no universal numeric scale (unlike, say, cholesterol measured in mg/dL), you cannot compare an "IgM index" value from one lab to a value from another lab. Different manufacturers use different antigens, cutoffs, and units. A multi-laboratory comparison across 12 Northern European clinical labs found high agreement when labs used the same assay but substantially lower agreement when different assays were compared. A separate study comparing results from 4 U.S. laboratories found considerable inter-lab variability, with CDC two-tier criteria improving concordance.
Beyond the inherent false positive issues described above, several specific situations can make your Lyme IgM result unreliable.
Large Danish registry studies involving over 400,000 matched individuals have examined whether Borrelia seropositivity is linked to serious health outcomes beyond the infection itself. In the short term (within one month of testing), people who tested positive for both IgM and IgG had about twice the risk of a heart rhythm problem called atrioventricular block (where electrical signals between the upper and lower heart chambers are delayed) compared to people who tested negative. This short-term finding likely reflects acute Lyme carditis, a known complication of active infection.
Over the long term, however, Borrelia seropositivity was not associated with increased risk of heart failure, pacemaker implantation, or other conduction disorders after adjusting for age, sex, diabetes, prior heart failure, and kidney disease. The same research group found no long-term increase in heart failure or heart muscle disease risk among people who tested positive. The elevated short-term risk disappeared once the acute infection was treated.
For the nervous system, serum IgM and IgG cannot reliably predict whether Borrelia has invaded the cerebrospinal fluid (the liquid surrounding the brain and spinal cord). In neuroborreliosis, the patterns of IgM and IgG in the spinal fluid do not follow a simple timeline. A study of 544 neuroborreliosis patients found no correlation between how long someone had symptoms and whether their spinal fluid showed IgM production, IgG production, or both.
One finding from the Danish registry studies warrants mention. Among people who were positive for both IgM and IgG, there was about a two-fold increased long-term risk of chronic lymphocytic leukemia (CLL), a slow-growing blood cancer, compared to those who tested negative. This association was specific to CLL and was not seen for other blood cancers or in people with isolated IgM or isolated IgG. The finding comes from a single large cohort and has not been replicated. It does not mean that Lyme infection causes leukemia, but it does suggest that people with both IgM and IgG positivity may warrant routine blood count monitoring.
For most biomarkers, serial tracking (retesting at intervals) is more valuable than a single reading. Lyme IgM is an exception to that general rule. Because IgM can persist for years after resolved infection and because the test has high inter-assay variability, repeatedly checking your Lyme IgM is not a useful way to monitor your health. A persistently positive IgM does not mean you have chronic active Lyme disease. A randomized trial of 281 patients with persistent symptoms attributed to Lyme found that longer courses of antibiotics provided no benefit over shorter courses, regardless of antibody status.
That said, if you have been diagnosed with early Lyme disease and treated, there are two situations where repeat testing can add information. First, if your initial test was done very early and was negative, retesting 2 to 4 weeks later can catch seroconversion and confirm the diagnosis. Second, if a positive IgM was your only serologic evidence, checking whether IgG develops over the following weeks can help distinguish a true early infection from a false positive. If IgG never appears, the original IgM positive is more likely to have been spurious. In the large Swedish-Danish registry, isolated IgM very rarely preceded later IgG seroconversion (only 0.23% of cases), further underscoring that isolated IgM is usually not the beginning of a real immune response to Borrelia.
If your Lyme IgM test is positive and you have clear symptoms of early Lyme disease (a spreading red rash, recent tick exposure in an endemic area, new-onset facial paralysis or joint swelling), the result supports the clinical diagnosis and treatment should proceed promptly with appropriate antibiotics. In this scenario, the test is doing its job.
If your Lyme IgM is positive but you do not have clear Lyme symptoms, or if your symptoms have been present for more than about 6 weeks, the result should be treated with skepticism. The next step is to check whether IgG is also positive. If only IgM is positive and IgG is negative, the result is more likely a false positive than evidence of active Lyme. Retesting in 2 to 4 weeks to look for IgG seroconversion can help clarify the picture.
If your result is negative and you are within the first week or two of potential exposure, it does not rule out Lyme disease. The test can miss early infections before your immune system has ramped up antibody production. If suspicion remains high based on your symptoms and exposure history, retesting in 2 to 4 weeks is appropriate.
If neurological symptoms are present (numbness, weakness, facial drooping, severe headache), an infectious disease specialist may recommend testing the cerebrospinal fluid directly for Borrelia-specific antibodies and a protein called CXCL13 that rises during infections of the central nervous system. These spinal fluid tests can be more informative than serum IgM for neuroborreliosis. A study of 161 children found that combining the Borrelia antibody index in spinal fluid with CXCL13 and total IgM index provided highly sensitive and specific diagnosis of Lyme neuroborreliosis.
Lyme Antibody (IgM) is best interpreted alongside these tests.